Rep. Julie Johnson Unloads Shares of Moderna, Inc. (NASDAQ:MRNA)

Representative Julie Johnson (D-Texas) recently sold shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on February 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on January 15th. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Dell Technologies (NYSE:DELL) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of ALLETE (NYSE:ALE) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 1/27/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/17/2025.

Moderna Trading Up 4.6 %

MRNA stock opened at $31.92 on Friday. The firm’s fifty day simple moving average is $39.31 and its two-hundred day simple moving average is $55.94. The stock has a market capitalization of $12.28 billion, a price-to-earnings ratio of -5.48 and a beta of 1.59. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a twelve month low of $30.24 and a twelve month high of $170.47.

Analysts Set New Price Targets

Several analysts have issued reports on MRNA shares. Bank of America decreased their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday. Leerink Partners decreased their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Evercore ISI reduced their target price on Moderna from $60.00 to $50.00 and set an “in-line” rating on the stock in a research note on Monday, January 27th. Finally, Berenberg Bank boosted their target price on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $66.89.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 2,664 shares of company stock worth $115,210 in the last ninety days. 15.70% of the stock is owned by insiders.

Institutional Trading of Moderna

Several hedge funds have recently modified their holdings of MRNA. Arkadios Wealth Advisors raised its stake in shares of Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after acquiring an additional 243 shares in the last quarter. Knuff & Co LLC increased its position in shares of Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after purchasing an additional 244 shares in the last quarter. Stephens Inc. AR lifted its holdings in shares of Moderna by 7.9% during the 3rd quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after purchasing an additional 245 shares during the last quarter. Allworth Financial LP boosted its position in shares of Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after purchasing an additional 281 shares in the last quarter. Finally, Howard Capital Management Inc. boosted its position in shares of Moderna by 3.1% in the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after purchasing an additional 297 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.